GC Corp. (KRX:005250)
South Korea · Delayed Price · Currency is KRW 9,970.00
-60.00 (-0.60%)
At close: Sep 1, 2026
GC Corp. Revenue
GC Corp. had revenue of 596.27B KRW in the quarter ending June 30, 2026, a decrease of -0.71%. This brings the company's revenue in the last twelve months to 2.49T, up 9.57% year-over-year. In the year 2025, GC Corp. had annual revenue of 2.45T with 11.19% growth.
Revenue (ttm)
2.49T
Revenue Growth
+9.57%
P/S Ratio
0.18
Revenue / Employee
17.27B
Employees
144
Market Cap
455.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.45T | 246.62B | 11.19% |
| Dec 31, 2024 | 2.20T | 146.92B | 7.14% |
| Dec 31, 2023 | 2.06T | -21.62B | -1.04% |
| Dec 31, 2022 | 2.08T | 239.00B | 12.99% |
| Dec 31, 2021 | 1.84T | 121.23B | 7.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medy-Tox | 251.08B |
| Onconic Therapeutics | 82.17B |
| MEDIPOST | 74.84B |
| Komipharm International | 53.02B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |
| GI Innovation | 5.63B |
| AbClon | 5.31B |
GC Corp. News
- 10 months ago - MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India - Business Upturn